Literature DB >> 11547217

Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.

B Guerci1, P Böhme, A Kearney-Schwartz, F Zannad, P Drouin.   

Abstract

Coronary artery, cerebrovascular and peripheral vascular disease, are the principal causes of morbidity and mortality in type 2 diabetes mellitus. The accelerated macrovascular disease in type 2 diabetes mellitus is due partly to the increased incidence of cardiovascular risk factors, such as hypertension, obesity and dyslipidemia. Advanced glycation end products, glycoxidised and oxidized low-density lipoproteins and reactive oxygen species linked to hyperglycemia have all been identified in type 2 diabetes mellitus and could accelerate macroangiopathy. Hence, the resistance to insulin is an additional independent risk factor, in association with oxidant stress, dyslipidemias, and prothrombic/hypofibrinolytic states. The endothelium is a major organ involved by cardiovascular risk factors, such as hypercholesterolemia, hypertension, inflammation, ageing, postmenopausal status, and smoking. Changes in endothelium function may lead to the coronary artery circulation being unable to cope with the increased metabolism of myocardial muscle independently of a reduced coronary artery diameter. The way endothelial function is altered in diabetic patients is not yet fully understood, but the loss of normal endothelial function could be involved in the pathogenesis of diabetic angiopathy, as endothelial dysfunction is associated with diabetic microangiopathy and macroangiopathy. Finally, recent reports indicate that an improved metabolic control in diabetic patients, whatever the treatment used, is associated with near normalization or restoration of normal endothelial function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547217

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  50 in total

1.  [The role of AGEs and ROS in atherosclerosis].

Authors:  Alin Stirban
Journal:  Herz       Date:  2010-05       Impact factor: 1.443

2.  The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus.

Authors:  A Cayir; R A Ugan; A Albayrak; D Kose; E Akpinar; Y Cayir; H T Atmaca; Z Bayraktutan; M Kara
Journal:  J Endocrinol Invest       Date:  2015-04-07       Impact factor: 4.256

3.  MicroRNA-181b regulates NF-κB-mediated vascular inflammation.

Authors:  Xinghui Sun; Basak Icli; Akm Khyrul Wara; Nathan Belkin; Shaolin He; Lester Kobzik; Gary M Hunninghake; Miguel Pinilla Vera; Timothy S Blackwell; Rebecca M Baron; Mark W Feinberg
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

Review 4.  Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?

Authors:  Petra Rocic
Journal:  Vascul Pharmacol       Date:  2012-02-09       Impact factor: 5.773

5.  Aminoguanidine changes hippocampal expression of apoptosis-related genes, improves passive avoidance learning and memory in streptozotocin-induced diabetic rats.

Authors:  Maryam Arab Firouzjaei; Mohammad Reza Jafari; Mehdi Eskandari; Iraj Jafari Anarkoli; Mohsen Alipour
Journal:  Cell Mol Neurobiol       Date:  2013-12-11       Impact factor: 5.046

Review 6.  Mechanisms of endothelial dysfunction in the metabolic syndrome.

Authors:  Prakash C Deedwania
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

7.  Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.

Authors:  K Swaminathan; J Davies; J George; N S Rajendra; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2008-03-18       Impact factor: 10.122

8.  Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin.

Authors:  Tracy Dodd; Luke Wiggins; Rebecca Hutcheson; Erika Smith; Alla Musiyenko; Brenda Hysell; James C Russell; Petra Rocic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-18       Impact factor: 8.311

9.  Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.

Authors:  A Schäfer; D Fraccarollo; S Pförtsch; U Flierl; C Vogt; J Pfrang; A Kobsar; T Renné; M Eigenthaler; G Ertl; J Bauersachs
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

10.  Glycemic status and brain injury in older individuals: the age gene/environment susceptibility-Reykjavik study.

Authors:  Jane S Saczynski; Sigurdur Siggurdsson; Palmi V Jonsson; Gudny Eiriksdottir; Elin Olafsdottir; Olafur Kjartansson; Tamara B Harris; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer
Journal:  Diabetes Care       Date:  2009-06-09       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.